(NASDAQ: CCCC) C4 Therapeutics's forecast annual revenue growth rate of 112.66% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
C4 Therapeutics's revenue in 2024 is $20,756,000.On average, 4 Wall Street analysts forecast CCCC's revenue for 2024 to be $1,795,622,511, with the lowest CCCC revenue forecast at $686,006,690, and the highest CCCC revenue forecast at $2,723,446,559. On average, 3 Wall Street analysts forecast CCCC's revenue for 2025 to be $1,799,601,350, with the lowest CCCC revenue forecast at $1,303,412,711, and the highest CCCC revenue forecast at $2,058,020,070.
In 2026, CCCC is forecast to generate $17,448,580,160 in revenue, with the lowest revenue forecast at $2,524,504,619 and the highest revenue forecast at $32,372,655,701.